Comprehensive Overview

The group was founded in 2017 as a biotechnology company headquartered in China and the United States. It mainly develops treatments for diseases including hepatitis B virus, HIV, and multiple drug resistance. The core product of the group is BRII-179, an HBV-specific B-cell and T-cell therapeutic vaccine. There is also a pipeline of other innovative products focusing on infectious diseases and CNS diseases. Pharmaceutical Kangde, Pharmaceutical Biotech, and several of their subsidiaries are among the Group's top five suppliers, providing CRO and/or CMO/CDMO services related to clinical development of candidate drugs to the Group.

Risk Factors

So far, the Group has not generated any revenue from product sales, and it is expected that commercial product sales will not be generated in the short term. The group also indicated that losses are expected to increase in 2021 due to continued clinical trial promotion, other clinical trials, and confirmation of potential losses related to the increase in the fair value of preferred shares before the global sale ends. Also, clinical trials are expensive, and it can take years to complete, and the results themselves are full of uncertainty.